Responses
Psoriatic arthritis
Original research
Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study of patients who were biologic-naïve or TNFα inhibitor-experienced
Compose a Response to This Article
Other responses
No responses have been published for this article.